Z
4.72
0.14 (3.06%)
| Penutupan Terdahulu | 4.58 |
| Buka | 4.69 |
| Jumlah Dagangan | 226,869 |
| Purata Dagangan (3B) | 434,595 |
| Modal Pasaran | 308,185,312 |
| Harga / Pendapatan (P/E TTM) | 8.28 |
| Harga / Buku (P/B) | 0.970 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Nov 2024 |
| EPS Cair (TTM) | -0.390 |
| Nisbah Semasa (MRQ) | 10.36 |
| Aliran Tunai Operasi (OCF TTM) | -21.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.87 M |
| Pulangan Atas Aset (ROA TTM) | -21.40% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Zura Bio Limited | Menurun | Menaik |
AISkor Stockmoo
-1.6
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.63 |
|
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 31.87% |
| % Dimiliki oleh Institusi | 58.01% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 15.00 (Leerink Partners, 217.80%) | Beli |
| Median | 12.00 (154.24%) | |
| Rendah | 5.00 (HC Wainwright & Co., 5.93%) | Pegang |
| Purata | 10.67 (126.06%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 3.75 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Dec 2024 | 5.00 (5.93%) | Pegang | 2.31 |
| 18 Nov 2024 | 5.00 (5.93%) | Pegang | 3.21 | |
| Chardan Capital | 08 Nov 2024 | 12.00 (154.24%) | Beli | 4.58 |
| Leerink Partners | 04 Nov 2024 | 15.00 (217.80%) | Beli | 4.37 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 Dec 2024 | Pengumuman | Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis |
| 25 Nov 2024 | Pengumuman | Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference |
| 14 Nov 2024 | Pengumuman | Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis |
| 07 Nov 2024 | Pengumuman | Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates |
| 30 Oct 2024 | Pengumuman | Zura Bio to Participate in Two Upcoming Investor Conferences in November |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |